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Importance: The prescription of generic (non-proprietary) compared to brand-name
drugs is increasing worldwide. In many developing and emerging countries, generics
companies market products at similar costs as brand-name competitors benefiting
from more flexible compliance rules and regulations for marketing their products in
the health system. Together, this phenomenon may influence prescriber’s behavior
(e.g., maintaining the same treatment despite guideline’s recommendations or despite
evidence of disease progression).
Objectives: To compare the prevalence of therapeutic inertia (TI) between primary
prescription of brand-name vs. generic drugs in the management of MS in Argentina.
Design: We conducted a population-based online study comprising 117 neurologists
with expertise in MS. Participants answered questions regarding their clinical practice,
most commonly prescribed disease modifying agents, and therapeutic choices of
10 simulated case-scenarios that assessed TI. Inertia was defined as the lack of
treatment initiation or escalation despite evidence of clinical and radiological activity (8
case-scenarios, 720 individual responses). We created the generic-brand name score
(GBS) according to the 5most frequently prescribed generic (n= 16) vs. brand-name (n=
9) drugs for MS, where scores higher than 1 indicated higher prescription of generic drugs
and scores lower than 1 indicated higher prescription of brand-name agents. Candidate
predictors of prescribing generic drugs included demographic data, MS specialist vs.
general neurologist, practice setting, years of practice, volume of MS patients, risk
preferences, costs of annual treatment.
Participants and setting: population-based prospective study using including
neurologists who care for patients with multiple sclerosis across Argentina.
Exposure: prescription of generic vs. brand-name MS drugs
Main outcome of interest: Therapeutic inertia (TI), defined as lack of treatment
escalation when goals are unmet. Secondary outcomes included factors associated with
generic drug prescription and costs of MS treatment.
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Results: Ninety participants completed the study (completion rate 76.9%). TI was
observed in 153 (21.3%) of participants’ responses. The evaluation of aggregate
responses revealed a mean GBS score (SD) of 3.44 (2.1), with 46 (51.1%) participants
having a GBS equal to or higher than 1. Older age (OR 1.19; 95% CI 1.00–1.42), being a
general neurologist (OR 3.91; 95% CI 1.19–12.8), and being more willing to take risks in
multiple domains (SOEP score OR 1.06, 95% CI 1.01–1.12) were associated with higher
prescription of generic drugs in MS care. Costs of treatment were not associated with
prescribing generic drugs. There was no difference in the annual costs of MS treatment
for primary prescribers of brand-name vs. generic drugs (67,500 US$ vs. 67,496 US$;
p = 0.99).
The evaluation of individual responses revealed that participants with higher prescription
of generics—reflected by a higher GBS—had higher incident risk of TI (mean GBS 3.61
for TI vs. 2.96 for no TI; p < 0.001). Multivariate analysis revealed that a prescription of
generic agents was associated with an increased incident risk of TI (OR 1.56; 95%CI
1.07–2.29). There was no difference in the annual costs of MS treatment for participants
that exhibited TI vs. those without TI (67,426 US$ vs. 67,704 US$; p = 0.66).
Conclusions: General neurologist, older age, and willingness to take risks were
associated with increased prescription of generic drugs despite similar costs compared
to brand-name agents. In our study, the prescription of generic-MS drugs was associated
with a higher incident risk of therapeutic inertia.
Keywords: multiple sclerosis, disease-modifying therapy, generic drugs, decision making, risk aversion, inertia,
outcomes
BACKGROUND
Therapeutic decisions in multiple sclerosis (MS) care are
becoming more complex with the recent advances of disease
modifying agents, varying dosage form (oral, injectables,
infusion), and side-effect profiles, currently counting 14 different
therapeutic alternatives (1, 2). Health authorities are responsible
for the approval of new drugs (brand-name and generics) and
regulatory policies to controlling pharmaceutical expenditures.
The Food and Drug Administration in the United States defines
a generic drug as a medication having the same active principle
as the marketed brand-name product in the same dosage
form with similar bioequivalence (e.g., efficacy, safety, strength,
performance characteristics, route of administration, approved
intended use, and quality) (3). Generic drugs are typically
less expensive than brand-name drugs. However, many low-
income and emergent countries do not have value-based or
market-based price strategies to regulate a competitive market
(4). Furthermore, pharmaceutical manufacturers of generic
drugs have more flexible internal rules of compliance and less
bureaucracy compared to brand-name companies obliged to
report to their head-offices (5). Together, these phenomena may
lead to different marketing strategies and higher profits of generic
companies (4, 6–11).
There is a wide variety of generic drug prescription across
countries andmedical conditions. A comparative study of generic
vs. brand-name drugs showed a dramatic increase in the market
share, with USA and Latin-American countries leading that
change (5). Argentina, a South-American country, has a low
prevalence (20 and 38 cases per 100,000 inhabitants) of MS
compared to Canada, USA and most European countries (over
60 cases per 100,000 inhabitants) (12, 13). The projected number
of MS patients in Argentina range between 3500 and 5000 (14).
Despite this relatively low number of patients, Argentina is one
of the leading countries with higher availability and prescription
of generic agents (n = 16; interferon, glatiramer, dimethyl-
fumarate, teriflunomide, fingolimod) for the management of
MS. Local regulatory authorities of Argentina do not require
bioequivalence studies for the approval of generic drugs. The
annual costs of MS treatment in Argentina are extremely high
(similar to the USA and other developed countries) ranging from
US$ 50,749 (Dimetyl-Fumarate) to US$ 94,342 (Natalizumab)
(http://www.alfabeta.net/precio, updated May 11, 2018 and
accessed May 13, 2018). The costs of generics are similar (or
higher) compared to brand-name drugs (Appendix). In other
words, the arrival of generic drugs to the market has not brought
a reduction in the annual costs for MS treatment (5).
We have limited information on physicians’ preferences
between generic vs. brand-name drugs forMS care and associated
outcomes. Given the aforementioned environment, we wanted to
study whether neurologists’ preferences for generics compared
to brand-name agents were associated to treatment escalation
when recommended by guidelines (4). The tendency to stay with
the status quo is called “therapeutic inertia” and defined as the
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absence of treatment initiation or intensification when treatment
goals are unmet (15–18). In the context of MS, TI is defined as the
lack of treatment initiation or escalation when there is evidence
of disease activity (based on the clinical course and neuroimaging
markers) (19, 20). Treatment escalation has been shown to reduce
relapse rates, disability progression, and MRI activity (21–24).
Observational real-world studies can provide insights into factors
associated with treatment response, comparative effectiveness
of disease modifying therapies that are useful for directing
daily clinical practice (25). Yet, it remains unknown whether
generic drug prescription is associated with TI. Accordingly,
the aims of this study were: (i) to evaluate the prevalence of
generic drug prescription for the management of MS, (ii) to
identify prescribers’ associated factors, and (iii) to determine
the association between prescription of generic-drugs and TI.
Specifically, we hypothesized that prescribers of generic (non-
proprietary) drugs may exhibit higher prevalence of TI for MS
care.
METHODS
We completed a web-based study among practicing neurologists
who were prescribers of MS drugs in Argentina from March 30,
2018 to April 30, 2018 and collected data on: (i) demographic
information, (ii) behavioral experiments/surveys, and (iii) 10
case-scenarios that assessed therapeutic inertia. MS case-
scenarios were derived from the most common situations in
clinical practice as identified by experts in the field and previously
published elsewhere (19). Participants had to select those MS
drugs that they use and then rank them from a list including
all available agents approved by the local regulatory body in
Argentina by March 30, 2018. The purpose of this strategy was
to examine the prefererence for prescribing generic drugs over
brand-name drugs. Participants were also asked if they had any
restriction to prescribe generic vs. brand-name MS drugs at their
workplace.
We used risk-related questions of the Socio-Economic Panel
(SOEP), a validated German survey that, among other things,
assesses willingness to take risks in 6 different domains (26)
Typical questions include: “How would you rate your willingness
to take risks in the following areas. . . .?” Areas included financial
matters, driving, own occupation, own health, sports, and trust
in others. Responses could range from 0 (not at all) to 10
(very much). A summary SOEP score is created with the ratings
given to each question, ranging from 0 to 60 (higher ratings
corresponding to higher willingness to take risk in all domains).
Behavioral experiments were designed to assess participants’ risk
preferences and ambiguity aversion in the health and financial
domains (27, 28). In brief, ambiguity aversion is defined as
dislike for events with unknown probability over events with
known probability (27). For example in the medical domain,
an ambiguity-averse individual would rather choose a treatment
where the probability of benefits or side effects is known
(even if these are somewhat unfavorable) over one where this
probability is unknown. In our task, participants were asked to
choose between a visual option with known 50/50 probability of
winning 400 or 0 American dollars vs. an option with unknown
probability of the same outcomes. The width of gray bars
occluding exact probability information represented the degree
to which the winning probability was unknown. Risk aversion is
defined as the tendency to prefer safe payoffs over probabilistic
payoffs when the expected value of both options is identical
(27, 29). Further details of these experiments were published in
previous studies (30).
Participants
117 practicing neurologists actively involved in the care of
patients with MS from across Argentina were invited to
participate by the Institute of Neurosciences Buenos Aires
(INEBA) with the support and endorsement of the Argentinian
Society of Neurology (through the Demyelinating Diseases
Working Group). Physicians whose practice was primarily in
caring for MS patients were classified as “MS specialists.” All
participants received compensation for completing the survey.
The study was approved by the Research Ethics Board of St.
Michael’s Hospital, University of Toronto, Canada.
Definitions
Generic (non-proprietary) agents were defined according to
the Food and Drug Administration description as follows:
a pharmaceutical drug that is equivalent to a brand-name
product in dosage, strength, route of administration, quality,
performance, and intended use. Costs of MS drugs were derived
from http://www.alfabeta.net/precio (updated May 11, 2018
and accessed May 13, 2018). In order to evaluate participant
preference for prescribing generic over brand-name drugs, we
created the generic-brand score (GBS). The GBS was based
on participants’ five most frequently prescribed drugs for MS.
Our aim was to identify participants who primarily prescribe
brand-name drugs vs. those who prescribe generic drugs or
were indifferent to this dichotomy. Participants had to order MS
drugs and also indicate non-prescribed drugs on a different list.
We initially created a subscore for the total number of brand-
name drugs from the top five list of brand-name drugs (n =
9) selected by each participant. A similar subscore was created
for the total number of generic drugs from the top five list of
generic drugs (n = 16). To avoid subscores of zero, we added
one point to both subscores. GBS was calculated by dividing the
generic subscore by the brand-name subscore. For example, if
a participant chose 5 generic-drugs and 3 brand-name drugs,
GBS would be (5 + 1)/(3 + 1) = 1.5. Similarly, if a participant
chose 1 generic drug and 5 brand-name drugs, the GBS would be
(1+ 1)/(5 + 1) = 0.33. Scores equal to or higher than 1 indicate
indifference or higher prescription of generic drugs, scores lower
than 1 indicate higher prescription of brand-name agents. We
also tested other definitions of the GBS (using the most or the
three most prescribed drugs of each type), which did not alter the
results.
Disease activity was defined as a clinical relapse plus the
presence of new brain lesions in follow-up magnetic resonance
imaging (MRI) scans with at least one gadolinium-enhancing
lesion (31, 32). The high-risk profile according to the modified
Rio score includes an MRI with more than 5 new T2 lesions (1
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point), 1 relapse in the first year (1 point), two relapses within
the first year of treatment (2 points) or the combination of these
criteria (23, 33). The use of these definitions combining a clinical
relapse and MRI activity is consistent with recent evidence
regarding the risk of treatment failure among patients receiving
interferon-β (34). Disease progression was defined as at least one
point worsening from baseline in the Expanded Disability Status
Scale (EDSS) score (33). In Argentina, the local Consensus on
treatment failure in RRMS was in agreement with the current
available recommendations (12). Recentmeta-analysis confirmed
that alemtuzumab, natalizumab, and fingolimod are the best
available choices for preventing clinical relapses in patients with
relapsing-remitting MS (35). We use the paradigm of first-line
therapies (beta interferons, glatiramer acetate, teriflunomide,
and dimethyl fumarate) and second-line therapies (fingolimod,
natalizumab, alemtuzumab) for the present study.
Outcome Measures
The primary outcome of the study was the prevalence of
participants’ preference for generic drugs determined by the
GBS score. We also assessed factors associated with participant’s
preference for generic drug prescription. A secondary outcome
was the association between the GBS score and TI. We used two
operative definitions of TI: (i) Categorical TI was defined as lack
of treatment initiation or escalation in at least one out of eight
case-scenarios; (ii) TI score: participants were given 1 point for
each answer that met the TI definition; this score ranged from 0
(lowest TI) to 8 (highest TI).
Statistical Analysis
The primary analysis assessed the possible association between
generic drug prescription, as measured by the GBS, and TI (as
a categorical variable and as a continuous score). We compared
baseline characteristics between participants who primarily
prescribe generic (GBS ≥ 1) vs. brand-name (GBS < 1) drugs. A
multivariate logistic regression analysis with backward selection
was completed to determine the association between participants’
characteristics with TI (primary outcome of interest). Linear
regression analysis was used to test for a relation between TI
score and GBS. We also conducted random effect analyses where
participants (n = 90) and individual responses (8 case-scenarios
potentially contributing to TI for each of the 90 participants’
720 individual responses) entered as random effects. The aim of
this analysis is to evaluate the contribution of individuals to the
variation of TI.
We included the following explanatory variables: age, gender,
MS patients seen per week, number of years of practice, practice
setting (academic vs. non-academic), % of time devoted to
clinical care, co-author in a peer reviewed publication within the
last year (yes/no), risk preferences, willingness to take risks in
all domains (SOEP survey score as a continuous variable). We
also compared the average costs of annual MS treatment between
participants who primarily prescribe generic and brand-name
drugs and analyzed these costs in relation to TI. A mediation
analysis was completed to determine whether the association
between GBS and TI was mediated by the main factors associated
with generic prescription: age, SOEP and specialists status. We
used the STATA command “paramed” for the mediation analysis
(see details of the models in theAppendix) (36, 37). All tests were
2-tailed, and p-values < 0.05 were considered significant. We
used STATA 13 (College Station, TX: StataCorp LP) to conduct
all analyses.
RESULTS
Out of the 117 neurologists with expertise in MS care who
were invited to participate in the study, 90 completed the
survey (response rate 76.9%). There was representation from all
territories (Figure 1). The mean (SD) age was 46.4 (±10.3) years;
48 (53%) were male neurologists. Thirty one (34.4%) participants
primarily focused their practice on MS care. The mean years
(SD) in practice was 20.3 (±10.9), commonly assessing 22 (±6.6)
MS patients per week. Table 1 compares baseline characteristics
between participants who primarily prescribe generic (GBS ≥
1.0) and brand-name (BGS < 1.0) MS agents. Forty six (51.1%)
FIGURE 1 | Map representation of participating neurologists.
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TABLE 1 | Baseline characteristics of participants.
Characteristics GBS <1.0
N = 44
GBS ≥ 1.0
N=46
p-value
Age (mean ± SD), in years 46.0 ± 10.8 46.8 ± 9.9 0.70
Sex 0.06
Male 19 (43.2) 29 (63.0)
Female 25 (56.8) 17 (37.0)
Specialty 0.21
MS specialist 18 (40.9) 13 (28.3)
General Neurologist who care
for MS patients
26 (59.1) 33 (71.7)
Practice setting 0.77
Public 14 (31.8) 16 (34.8)
Private 30 (68.2) 30 (65.2)
% Time in Clinical Practice
>75% 17 (38.6) 22 (47.8) 0.38
Years in practice, mean (±SD) 20.4 ± 10.7 20.2 ± 11 0.94
MS patients seen per week,
mean (±SD)
22.2 ± 5.7 22.7 ± 7.5 0.74
Author of a peer-reviewed
publication in the last 1 year
23 (52.3) 20 (43.8) 0.40
Restriction to prescribe ms drugs 0.62
No restrictions 29 (65.9) 28 (60.9)
Average (SD) annual costs, in US$ 67,500
(2,596)
67,496 (2,672) 0.99
Conversion rate: 1 US$ = 23.0 AR$ (derived from www.xe.com; data accessed on May
12, 2018).
participants were classified as primary or equal prescribers of
generic drugs compared to brand-name agents. There was no
difference in themean annual costs for participants that primarily
prescribe generic compared to brand-name drugs. In line with
this finding, there was no difference in risk preferences between
groups as measured by the behavioral risk tasks (p= 0.40 for risk
preferences and p= 0.63 for aversion to ambiguity).
For the primary outcome, we evaluated factors associated with
the primary prescription of generic drugs. We found that older
age (OR 1.19; 95%CI 1.00–1.42), being a general neurologist (OR
3.91; 95%CI 1.19–12.8), and being more willing to take risks in
multiple domains (SOEP score OR 1.06, 95%CI 1.01–1.12) were
associated with higher propensity to prescribe generic drugs in
MS care. The c-statistics was 0.736, and goodness of fit test 0.35,
suggestive of an acceptable discrimination and good calibration.
Generic Prescription and Therapeutic
Inertia
TI was present in at least one case-scenario in 67 (74.4% of all)
participants (72.7% for participants with GBS < 1.0 vs. 76.1%
for participants with GBS ≥ 1.0; p = 0.21). TI was significantly
lower among participants who exclusively prescribe brand-name
drugs compared to their counterparts who prescribe at least some
generic drugs (50.0% vs. 79.7%; p = 0.01). Accordingly, the TI
score was significantly higher among participants who primarily
prescribe generic MS drugs (mean TI score 1.85 vs. 1.54; p <
0.001). Thus TI appears to be associated with the prescription
of generic drugs. In keeping with this conclusion, the analysis
of individual responses revealed that participants with TI had
higher GBS scores (increased prescription of generics) compared
to those without TI (mean GBS 3.61 vs. 2.96; p < 0.001). The
comparison of annual costs of MS drugs did not differ between
participants that exhibited TI vs. those without TI (67,426 US$ vs.
67,704 US$; p= 0.66). Further results are summarized in Table 2.
The multivariate analysis after adjusting for covariates (e.g.,
age, specialist vs. general neurologists, years of practice, GBS)
revealed that participants who primarily prescribe generic agents
exhibited a higher incident risk of TI (OR 1.56; 95% CI 1.07–
2.29). Similar findings were observed in the random-effect
models (OR 1.62; 95% CI 1.03–2.56). There was no significant
difference between fixed-effects and random effects models (p =
0.15).
The analysis of individual responses applying linear regression
models also showed that higher prescription of generic drugs
(represented by a higher GBS score) was associated with higher
TI scores (B coefficient 0.65; 95% CI 0.50–0.79). Similar results
were observed when the analysis was completed at the participant
level (B coefficient 0.64; 95% CI 0.007–1.27) (Table 2). The
addition of the annual mean costs of treatment did not alter the
results (B coefficient for GBS= 0.64; 95% CI 0.008–1.28).
The mediation analysis showed a persistent association
between prescription of generics (GBS) and TI. Specialist status
partially mediated the effect of generic prescriptions and TI,
explaining 11% of the association between the GBS and TI. There
were nomediation effects for age (p-value= 0.65), SOEP (p-value
= 0.97), or restriction to prescribe MS drugs (p-value = 0.25 on
the association between BGS and TI).
DISCUSSION
In the present study, we found that TI affected 7 out 10
participants in at least one case-scenario. The 50% of participants
who primarily (or equally) prescribed generic agents had a
50% higher incident risk of TI compared to those prescribing
brand-name drugs. Our results remained unchanged when
we compared fixed—and random-effects after adjusting for
confounders. Most common factors associated with primary
prescription of generic drugs include older age, being a general
neurologist (compared to a MS specialist), and being more
willing to take risks in multiple domains. The mediation analysis
revealed a modest effect of specialist status, explaining 11%
of the association between GBS score and TI. Restriction to
prescribe MS drugs by health insurers or health maintenance
organizations was not associated with TI. Interestingly, we found
no significant difference in the annual costs of MS treatments for
those who primarily prescribe generic vs. brand-name drugs. The
annual costs of MS drugs did not affect the association between
prescription of generics and the incident risk of TI.
The analysis of individual responses revealed that for every
100MS patients at high-risk of progression, there will be 23 who
will remain with the same treatment if managed by neurologists
who primarily (or equally) prescribe generic drugs. This is a
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TABLE 2 | Multivariate analysis for the primary outcome.
Outcome measures GBS < 1.0 GBS ≥ 1.0 Difference
between groups
Multivariate logistic analysis
(95%CI)*
Multivariate linear analysis
β coefficients (95%CI)†
n = 44 n = 46
TI (present vs. absent), n (%) 32 (72.7) 35 (76.1) (3.4) 2.01 (0.57–7.10) 0.64 (0.007–1.27)
TI present vs. absent at the
(individual responses)
68/352 (19.3) 85/368 (23.5) (4.2) 1.56 (1.07, 2.29) 0.65 (0.50, 0.79)
*Derived from multivariate logistic regression analysis for TI (present vs. absent). GBS, generic-brand score.
†
Derived from linear regression models and expressed in β coefficients (95%CI) with the TI score as the outcome measure.
All models adjusted for age, specialty, years of practice, and practice setting.
relevant figure given that prescription of generic drugs is well-
accepted and implemented by over 50% of neurologists from
Argentina even though the practice fails to reduce the annual
average costs for MS therapy. In addition to the known factors
associated with TI by our group in other countries (Spain, Chile,
Canada), the present study shows a relationship between the
prescription of generics and the presence of TI.
A limited number of studies showed differences in clinical
outcomes between generic vs. brand-name drugs. A brief
literature search in Pubmed combining MESH terms “generic,”
“brand,” and “outcomes” revealed 24 studies (accessed May 16,
2018). Three studies showed an improved adherence to generic
drugs. There is conflicting evidence regarding clinical outcomes
(38–40). For example, one meta-analysis including 7 studies
in epilepsy (n = 204) revealed no difference in the odds of
uncontrolled seizure (OR 1.1; 95% CI 0.9, 1.2) for patients on
generic medications compared with patients on brand-name
medications (38). Contrarily, another meta-analysis comprising
90,111 patients who initiated a statin [83,731 (93%) generic
drug, and 6380 (7%) initiated a brand-name drug] showed an
8% reduction in the incident risk of cardiovascular events (HR
0.92; 95% CI, 0.86–0.99) for prescribers of generic drugs (39).
There was an absolute difference of−1.53 events per 100 person-
years (CI, −2.69 to −0.19 events per 100 person-years) (39).
Contrarily, our study showed a higher incident risk of therapeutic
inertia with prescription of generic drugs.
Our results have limitations that deserve comment. First, our
sample size is relatively small. However, our study provides a
good representation of MS care across Argentina. Second, case-
scenarios may not necessarily reflect daily clinical practice. Third,
we cannot rule out the possibility that unmeasured confounders
(e.g., health policy, restrictive prescription rules) may contribute
to the studied outcome measures. We controlled for this issue
by measuring the prevalence of prescription restrictions in
the workplace for each participant. No association was found
between prescription restrictions and the outcomes of interest.
Fourth, the GBS has not been validated. However, our results
were not dependent on the exact definition of the GBS. Fifth,
the definition of TI applied to MS care is not widely used.
Nevertheless, we used a practical definition of TI (absence of
escalation in the face of a clinical relapse plus evidence of imaging
activity) consistent with our previous studies, which is supported
by guidelines showing improvements in clinical outcomes when
FIGURE 2 | Predicted TI scores by brand-name/generic ratio. Derived from
multivariate linear regression analysis with TI score as the outcome of interest.
p-value for GBS < 0.001.
escalating therapies (i.e., blood pressure and diabetes) (1, 12, 18,
41). Finally, although cost data was included, our study was not
designed as a cost-utility or cost-effectiveness study in MS.
The landscape of MS care is continuously evolving (42).
New and more effective agents are becoming available, but at
higher annual costs compared to their predecessors. Generic
drugs emerged with the intention of lowering the annual
treatment costs while having the same bioequivalence to
brand-name agents. However, local differences in regulatory
rules, costs (which are higher in the USA and Argentina
compared to European countries), quality of manufacturing, and
profits between brand-name and generic drugs impact on the
complexity of the health system as well as on prescription habits.
Our results revealed that, at least in the population of
neurologists surveyed in Argentina, the prescription of generic
medications was associated with a steep increase in TI (Figure 2),
with potential impact on patient outcomes.
This study vitally informs discussions regarding therapeutic
options available to treating physicians and patients, and
regarding price negotiations between policy-makers and
pharmaceutical companies.
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Our results have implications for Latin-America and other
countries with similar regulations for the approval of new
drugs and prescription of generic agents. Patients, the public,
taxpayers, pharmaceutical companies, academic institutions and
organizations, health care professionals, and governments all
strive for optimal outcomes by facilitating access to the best
possible care at the lowest possible price. As such, global
regulatory agencies (e.g., European Medicine Agency-EMA)
may have better mechanisms for approval of new drugs (e.g.,
Centralized system through Committees with representation
from different countries) compared to those where decisions
are made by a single or small number of individuals and
decentralized systems (43, 44). Garcia et al. summarized
differences between EMA, FDA, and other regulatory bodies in
Latin America, which may also explain cost disparities between
countries with centralized vs. decentralized regulatory systems
(44).
We need a better understanding on how the underlying health
regulations and incentives influence TI in MS care (6). Another
particular concern relates to the prevalence of misdiagnosis
in MS while those patients are currently receiving disease
modifying therapies (45, 46). For example, a recent study from
Argentina showed a diagnostic error rate of 32.8%, most of which
concerning treatment with MS drugs (47). We should reflect
on multifaceted factors (e.g., educational failures, permissiveness
of incentives, insurance coverage, lack of value- or cost-based
regulations, and drug costs) influencing decisions leading to TI in
MS care. An action plan today with the involvement of all players
could lead not only to better patient outcomes and quality of life,
but also to a better value for each dollar invested in MS care.
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